VivoSeq
Infectious Disease

Schistosomiasis

22

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Schistosomiasis is an emerging landscape with 22 programs across 6 companies. The most active players are Merck & Co., Pharco Pharmaceuticals, Dafra Pharma. 4 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

95/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

4 programs

Phase 2P

Pharco Pharmaceuticals

1 program

Phase 3D

Dafra Pharma

1 program

Phase 3Novartis logo

Novartis

2 programs

Phase 3Bayer logo

Bayer

1 program

ApprovedV

Vifor Pharma

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

87%

Small molecule

20 of 23 classified programs — the dominant modality here.

13%ALL OTHERSVaccine313%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

26

clinical trials

Completed20 · 77%
Unknown status4 · 15%
Recruiting1 · 4%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

26 trials

Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study
Recruiting·—·N/A·NCT06698510·18,500 enrolled
Arachidonic Acid Treatment Against Schistosomiasis Infection in Children
Completed·Ddsm-firmenich Switzerland AG·N/A·NCT02144389·335 enrolled
Single-sex Female Controlled Human Schistosomiasis Mansoni Infection
Completed·LLeiden University Medical Center·N/A·NCT04269915·13 enrolled
Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)
Completed·LLeiden University Medical Center·Phase 3·NCT02868385·167 enrolled
Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children
Completed·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT03893097·726 enrolled
Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding
Completed·LLeiden University·N/A·NCT02755324·17 enrolled
Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
Completed·OOswaldo Cruz Foundation·Phase 1·NCT01154049·20 enrolled
Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology
Completed·UUniversity of Toronto·Phase 4·NCT02878564·34 enrolled
Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
Completed·DDBL -Institute for Health Research and Development·N/A·NCT00276224·480 enrolled
Safety and Efficacy of Mirazid for Schistosomiasis Treatment
Completed·PPharco Pharmaceuticals·Phase 3·NCT01529710·200 enrolled
Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil
Completed·OOswaldo Cruz Foundation·Phase 4·NCT00403611·196 enrolled
Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis
Completed·UUniversity Hospital, Lille·Phase 1·NCT01512277·24 enrolled
Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis
Completed·DDafra Pharma·Phase 2/3·NCT00510159·800 enrolled
An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT02806232·444 enrolled
Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children
Completed·OOswaldo Cruz Foundation·Phase 2·NCT03799510·95 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)